TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Cellares Stock

Cellares Stock

www.cellares.com/Healthcare / Healthcare providers & servicesFounded: 2019Funding to Date: $355.75MM

Cellares, founded in 2019, is a cell therapy manufacturer that strives to develop scalable solutions to accelerate care for people living with a range of diseases. The company is the first Integrated Development and Manufacturing Organization (IDMO), and its Cell Shuttle platform aims to use automation to increase productivity at facilities that manufacture cell therapies for both autologous and allogeneic processes. Cellares is headquartered in San Francisco, California.

Buy or sell Cellares stockLearn more about Cellares IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Cellares, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Cellares’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cellares.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Cellares investors also invested in these private companies

8VC
Koch Disruptive Technologies
Bristol Myers Squibb
Eclipse Ventures
Decheng Capital

Team

Management Team

Fabian Gerlinghaus
Co-Founder & Chief Executive Officer
Omar Kurdi
Co-Founder & President
Gary Lo
Chief Financial Officer

Board Members

Justin Butler
Eclipse Ventures
Victor Tong Jr.
Decheng Capital

Frequently Asked Questions About Cellares’ Stock

plusminus
Can you buy Cellares’ stock?
Cellares is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cellares’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Cellares’ stock?
Yes, you can sell stock of a private company like Cellares. Forge can help you sell your Cellares stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Cellares’ stock price?
Cellares is a privately held company and therefore does not have a public stock price. However, you may access Cellares’ private market stock price with Forge Data.
plusminus
What is Cellares’ stock ticker symbol?
Cellares does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Cellares in the Healthcare providers & services sector

Mark Cuban Cost Plus Drug Company

Sector
Healthcare / Healthcare providers & services
 
 

Solv Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$399.84MM

SWORD Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$1.81B

HeartFlow

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$1.65B

VillageMD

Sector
Healthcare / Healthcare providers & services
 
 

Capsule

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$458.12MM

SnapNurse

Sector
Healthcare / Healthcare providers & services
 
 

Dandy

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$10.41MM

Collective Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$281.98MM

News Highlights

Fierce Pharma 08/24/2023
Cellares unveils $255M investment round with Bristol Myers among those in the fold
Wednesday, Cellares revealed a $255 million series C investment round to complete construction of its commercial-scale cell therapy manufacturing facility in Bridgewater, New Jersey. The fresh funding follows an $82 million series B round in 2021 and brings total backing in the company to $355 million.

Trending Companies

Frequently Asked Questions

Updated on: Apr 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.